Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Analysis of Revenues

Microsoft Excel

Paying users area

The data is hidden behind: . Unhide it.

  • Get 1-month access to Celgene Corp. for $22.49, or

  • get full access to the entire website for at least 3 months from $62.19.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Revenues as Reported

Celgene Corp., income statement, revenues

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
REVLIMID®
POMALYST®/IMNOVID®
OTEZLA®
ABRAXANE®
IDHIFA®
VIDAZA®
Azacitidine for injection
THALOMID®
ISTODAX®
Other
Net product sales

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

Item Description The company
Net product sales Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Celgene Corp. net product sales increased from 2016 to 2017 and from 2017 to 2018.